Efficacy and Safety Of Ponatinib Following Failure Of Nilotinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial
Year: 2013
Type: article
Source: Blood
Authors: Hagop M. Kantarjian, Jorge E. Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp D. le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H Jean Khoury, Moshe Talpaz, John F. DiPersio, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C. Müller, Carlo Gambacorti-Passerini, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G. Haluska, Francois Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, John M. Goldman, Neil P. Shah
Institutions: The University of Texas MD Anderson Cancer Center, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, Moffitt Cancer Center, Charité - Universitätsmedizin Berlin, University of California, Los Angeles, Ronald Reagan UCLA Medical Center, Singapore General Hospital, Hôpital Lyon Sud, Imperial College London, Emory University, Winship Cancer Institute, University of Michigan, Washington University in St. Louis, Dana-Farber Cancer Institute, University of Rome Tor Vergata, St. Eugenio Hospital, Hôpital Saint-Louis, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, University Medical Centre Mannheim, Azienda Ospedaliera San Gerardo, University of Milano-Bicocca, ARIAD Pharmaceuticals (United States), Inserm, Centre Hospitalier Universitaire de Poitiers, Huntsman Cancer Institute, Jena University Hospital, South Australia Pathology, South Australian Health and Medical Research Institute, University of California, San Francisco
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4236844282